Literature DB >> 3857041

delta 12-Prostaglandin J2, an ultimate metabolite of prostaglandin D2 exerting cell growth inhibition.

S Narumiya, M Fukushima.   

Abstract

L-1210 murine leukemia cells were exposed to prostaglandin D2 (PGD2), 10 micrograms/ml, in culture medium for various time, and subsequent cell growth was observed. More than 24 h exposure to PGD2 was required to inhibit cell growth almost completely. During this period, PGD2 degraded time-dependently into several products. The major product was identified as delta 12-PGJ2 by TLC, UV and mass spectra. When delta 12-PGJ2 was added to cells instead of PGD2, it evoked growth inhibition with much shorter contact time than PGD2. In addition, when the medium containing PGD2 was preincubated at 37 degrees C for 24 h, it elicited growth inhibition with only 6 h contact with cells. Furthermore, when the medium containing PGD2 was changed every 6 h during 24 h exposure time to cells, no significant growth inhibition was observed. These results suggested that PGD2 per se has little, if any, growth inhibitory activity, and delta 12-PGJ2 is an ultimate metabolite exerting growth inhibition. This action appears to be independent of cAMP, since delta 12-PGJ2 was virtually inactive in raising intracellular cAMP levels.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3857041     DOI: 10.1016/s0006-291x(85)80005-x

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  The cyclopentenone prostaglandin 15d-PGJ2 inhibits the NLRP1 and NLRP3 inflammasomes.

Authors:  Nolan K Maier; Stephen H Leppla; Mahtab Moayeri
Journal:  J Immunol       Date:  2015-02-13       Impact factor: 5.422

2.  Inactivation of wild-type p53 tumor suppressor by electrophilic prostaglandins.

Authors:  P J Moos; K Edes; F A Fitzpatrick
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

3.  Effects of cytotoxic prostaglandin, delta 12-PGJ2 on protein synthesis and cytoskeleton in transformed epidermal cells in culture.

Authors:  K Ikai; M Fukushima
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

4.  Adjuvant effects of antineoplastic prostaglandins to cisplatin in nude mice bearing human ovarian cancer cells.

Authors:  Y Kikuchi; T Kita; M Miyauchi; J Hirata; H Sasa; I Nagata; M Fukushima
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 5.  Follicular Fluid: A Powerful Tool for the Understanding and Diagnosis of Polycystic Ovary Syndrome.

Authors:  Ana Teresa Brinca; Ana Cristina Ramalhinho; Ângela Sousa; António Hélio Oliani; Luiza Breitenfeld; Luís A Passarinha; Eugenia Gallardo
Journal:  Biomedicines       Date:  2022-05-27

Review 6.  Preclinical studies of antitumor prostaglandins by using human ovarian cancer cells.

Authors:  Y Kikuchi; T Kita; J Hirata; M Fukushima
Journal:  Cancer Metastasis Rev       Date:  1994-12       Impact factor: 9.264

7.  Inhibitory effects of prostaglandin D2 against the proliferation of human colon cancer cell lines and hepatic metastasis from colorectal cancer.

Authors:  T Yoshida; S Ohki; M Kanazawa; H Mizunuma; Y Kikuchi; H Satoh; Y Andoh; A Tsuchiya; R Abe
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

8.  Growth inhibition of Friend erythroleukaemia cell tumours in vivo by a synthetic analogue of prostaglandin A: an action independent of natural killer-activity.

Authors:  S Marini; A T Palamara; E Garaci; M G Santoro
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

9.  CXCR4 in Cancer and Its Regulation by PPARgamma.

Authors:  Cynthia Lee Richard; Jonathan Blay
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

10.  Release of prostaglandin D2 by murine mast cells: importance of metabolite formation for antiproliferative activity.

Authors:  C Haberl; L Hültner; A Flügel; M Falk; S Geuenich; W Wilmanns; C Denzlinger
Journal:  Mediators Inflamm       Date:  1998       Impact factor: 4.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.